ABIONYX Pharma's CER-001 on Fast Track After Successful FDA Pre-IND Meeting

ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) is a biotech firm focused on developing innovative therapies using the world's only natural recombinant apoA-I, announced today that it has successfully completed a pre-IND (Investigational New Drug Application) meeting with the US FDA and has received feedback supporting an IND filing for its candidate drug.

This is a crucial endorsement of the project's quality and a major move towards including American study centres in upcoming clinical trials. ABIONYX Pharma plans to submit an IND application to the US authorities in the next few months.ABIONYX Pharma is a cutting-edge biotech company dedicated to creating innovative treatments for diseases that currently have no effective or existing therapies, including rare conditions.

Utilizing their deep expertise in lipid science and a unique apoA-I-based technology platform, the company accelerates the development of new therapeutics. ABIONYX Pharma is focused on significantly enhancing treatment outcomes for Sepsis and critical care patients.